Highlights faulty FDA review WASHINGTON, Jan. 27, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provides an update on the tradipitant ...

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provides an update on the tradipitant development program.

A woman living with a debilitating condition says she has been forced to spend nearly £40,000 on private healthcare after the NHS said they ...

Ozempic is synonymous with weight loss for many people. Doctors explain benefits and risks of semaglutide and other GLP-1 ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

Popular GLP-1 medications for weight loss and diabetes may have unexpected benefits for reducing risks for conditions ...

The study in Nature Medicine explores the potential wider benefits and risks of diabetes drugs GLP-1 receptor agonists.

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.